{
  "event_id": "9bd59cd16d13",
  "ticker": "AMGN",
  "company_name": "Amgen",
  "drug_name": "BLINCYTO",
  "result": "approved",
  "pdufa_date": "2017-05-03",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:E1910 trial, TOWER trial",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.100527",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "CD19+ Ph- B-cell precursor ALL",
    "source": "websearch:E1910 trial, TOWER trial",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.100529",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "blinatumomab",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:11:33.226880",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.445169",
    "error": null
  },
  "mechanism_of_action": {
    "status": "found",
    "value": "BiTE (CD19/CD3)",
    "source": "legacy_migration",
    "confidence": 0.75,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": "2026-01-10T12:42:32.008034",
    "error": null,
    "note": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:11:33.226880",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:E1910 trial, TOWER trial",
    "confidence": 0.95,
    "evidence": [
      "E1910 trial, TOWER trial"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.100510",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "0.002",
    "source": "websearch:E1910 trial, TOWER trial",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.100518",
    "error": null
  },
  "effect_size": {
    "status": "found",
    "value": "HR 0.41 for OS; 3-year OS 84.8% vs 69%",
    "source": "websearch:E1910 trial, TOWER trial",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.100522",
    "error": null
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "p_value_numeric": 0.002,
  "nct_ids": [
    "NCT02013167",
    "NCT02393859"
  ],
  "phase3_study_names": [
    "A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)",
    "Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL"
  ],
  "prior_crl_reason": null,
  "enrollment": {
    "count": 405,
    "type": "ACTUAL",
    "nct_id": "NCT02013167",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:24:41.540954"
  },
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": true
  },
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "date": null,
    "outcome": null,
    "vote_for": null,
    "vote_against": null
  },
  "is_single_arm": {
    "value": false,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=PARALLEL",
      "allocation=RANDOMIZED"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-10T13:11:33.758214",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "global",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['AUSTRALIA', 'BELGIUM', 'ISRAEL', 'CZECHIA', 'POLAND']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-10T13:11:33.758265",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "is_biosimilar": {
    "value": false,
    "status": "found",
    "source": "known_originators_db",
    "confidence": 0.95,
    "tier": 1,
    "evidence": [
      "originator: blincyto"
    ],
    "searched_sources": [
      "known_db",
      "patterns",
      "suffix_pattern",
      "approval_type"
    ],
    "last_searched": "2026-01-10T23:29:31.260962",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "is_first_in_class": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "crl_reason_type": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "warning_letter_date": {
    "value": "2014-01-27",
    "status": "found",
    "source": "fda.gov",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [
      "Thousand Oaks CA facility - drug/device combo violations (Prolia, Enbrel prefilled syringes)"
    ],
    "searched_sources": [
      "fda.gov"
    ],
    "last_searched": "2026-01-11T04:05:14.878568",
    "error": null,
    "note": null
  },
  "fda_483_date": {
    "value": "2023-05-01",
    "status": "found",
    "source": "redica.com",
    "confidence": 0.8,
    "tier": 3,
    "evidence": [
      "Facility: Thousand Oaks, CA",
      "Outcome: N/A"
    ],
    "searched_sources": [
      "redica.com"
    ],
    "last_searched": "2026-01-11T05:25:26.296544",
    "error": null,
    "facility": "Thousand Oaks, CA"
  },
  "fda_483_observations": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "cdmo_name": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "pai_date": {
    "value": null,
    "status": "not_found",
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T13:30:46.700494",
    "error": null,
    "note": null,
    "has_value": false,
    "needs_retry": true,
    "is_complete": false
  },
  "clinical_hold_history": {
    "value": null,
    "status": "confirmed_none",
    "source": "websearch_clinical_hold",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [
      "websearch_clinical_hold"
    ],
    "last_searched": "2026-01-10T13:30:47.904787",
    "error": null,
    "note": null,
    "has_value": false,
    "needs_retry": false,
    "is_complete": true
  },
  "days_to_pdufa": -3174,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:37.196948",
  "original_case_id": "5c53c31b182d",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:22:54.630082",
  "enriched_at": "2026-01-11T17:32:52.640472",
  "needs_manual_review": false,
  "review_reasons": [],
  "migrated_at": "2026-01-10T12:42:32.008055",
  "schema_version": "3.0",
  "adcom_scheduled": {
    "value": true,
    "status": "found",
    "source": "websearch_adcom",
    "confidence": 0.75,
    "tier": 3,
    "evidence": [
      "FDA Briefing Document Oncologic Drugs Advisory Committee ...",
      "FDA Panel Backs Blinatumomab for MRD+ ALL - OncLive",
      "Vote ratio extracted: 66.7%"
    ],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:32:52.640461"
  },
  "adcom_vote_ratio": {
    "value": 0.6666666666666666,
    "status": "found",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [
      "FDA Briefing Document Oncologic Drugs Advisory Committee ...",
      "FDA Panel Backs Blinatumomab for MRD+ ALL - OncLive",
      "Vote ratio extracted: 66.7%"
    ],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:32:52.640468"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA APPROVES BLINCYTOÂ® (BLINATUMOMAB) IN CD19 ... - Amgen"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T17:28:29.417717",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA expands approval of Blincyto for treatment of a type of ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T17:28:32.154384",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T17:28:38.891886",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA expands approval of Blincyto for treatment of a type of ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T17:28:30.709578",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA granted accelerated approval to blinatumomab (Blincyto ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T17:28:40.171191",
    "search_status": "FOUND"
  }
}